CAMBRIDGE, Mass., April 17, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today announced it will present ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results